Tyler S. Nelson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tyler S. Nelson has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Rajesh Khanna
University of Florida
12 shared publications Heather N. Allen
Department of Pharmacology and Therapeutics, McKnight Brain Institute, and Center for Advanced Pain Therapeutics and Research (CAPToR), College of Medicine, University of Florida, Gainesville, Florida, USA
10 shared publications- Bradley K. Taylor
Department of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
9 shared publications Aida Calderon-Rivera
Department of Pharmacology and Therapeutics, McKnight Brain Institute, and Center for Advanced Pain Therapeutics and Research (CAPToR), College of Medicine, University of Florida, Gainesville, FL 32610, USA
4 shared publications- Heather N. Allen
Department of Anesthesiology and Perioperative Medicine, Center for Neuroscience, Pittsburgh Center for Pain Research, Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
4 shared publications Kimberly Gomez
Department of Pharmacology and Therapeutics, McKnight Brain Institute, and Center for Advanced Pain Therapeutics and Research (CAPToR), College of Medicine, University of Florida, Gainesville, FL 32610, USA
4 shared publications
Latest Publications
- Open Access
A mouse model of myotonic dystrophy type 1 exhibits pain-like behavior and peripheral nociceptor hyperexcitability
Pain is a prevalent and disabling symptom of myotonic dystrophy type 1 (DM1), yet its underlying mechanisms remain poorly understood. Using HSA LR20b transgenic mice, we found multimodal mechanical and thermal hypersensitivity. Whole-cell electrophysiological recordings demonstrated depolarized resting membrane potentials and increased action potential firing selectively in small- and medium-diameter dorsal root ganglion neurons. These findings identify peripheral nociceptor sensitization as a potential mechanism contributing to pain in DM1.
Open AccessA mouse model of myotonic dystrophy type 1 exhibits pain-like behavior and peripheral nociceptor hyperexcitability
Pain is a prevalent and disabling symptom of myotonic dystrophy type 1 (DM1), yet its underlying mechanisms remain poorly understood. Using HSA LR20b transgenic mice, we found multimodal mechanical and thermal hypersensitivity. Whole-cell electrophysiological recordings demonstrated depolarized resting membrane potentials and increased action potential firing selectively in small- and medium-diameter dorsal root ganglion neurons. These findings identify peripheral nociceptor sensitization as a potential mechanism contributing to pain in DM1.
- Open Access
NaV1.7-dependent peripheral sensitization drives chronic pain in Parkinson's disease
Pain is among the most prevalent and disabling nonmotor symptoms of Parkinson's disease (PD), yet its mechanisms remain poorly defined and effective treatments are limited. Safinamide is one of the few drugs reported to improve pain in PD, but the mechanism underlying this effect is unknown. Here, we show that nigrostriatal neurodegeneration produces persistent hyperexcitability of primary sensory neurons associated with dysregulation of the voltage-gated sodium channel NaV1.7. In a brain-restricted 6-hydroxydopamine (6-OHDA) model, small-diameter dorsal root ganglion (DRG) neurons exhibited increased sodium current density and altered voltage-dependent inactivation, with the excess current eliminated by selective NaV1.7 blockade. Safinamide directly inhibited a NaV1.7-dependent component of sensory neuron sodium current and reversed established pain-like behaviors. Pharmacological disruption of NaV1.7 regulation by collapsin response mediator protein 2 (CRMP2) normalized DRG hyperexcitability and reversed mechanical and thermal hypersensitivity, whereas genetic disruption of the NaV1.7 CRMP2 regulatory sequence prevented the development of 6-OHDA-induced pain-like behaviors for up to 30 weeks despite preservation of the Parkinsonian motor phenotype. Transcriptomic profiling of human PD DRGs revealed limited global transcriptional remodeling with selective alterations in genes associated with sensory neuron excitability. Together, these findings demonstrate that dopaminergic neurodegeneration initiated within the brain is sufficient to drive persistent peripheral sensory neuron dysfunction and identify CRMP2-dependent regulation of NaV1.7 as a therapeutic target for Parkinsonian pain.
Open AccessNaV1.7-dependent peripheral sensitization drives chronic pain in Parkinson's disease
Pain is among the most prevalent and disabling nonmotor symptoms of Parkinson's disease (PD), yet its mechanisms remain poorly defined and effective treatments are limited. Safinamide is one of the few drugs reported to improve pain in PD, but the mechanism underlying this effect is unknown. Here, we show that nigrostriatal neurodegeneration produces persistent hyperexcitability of primary sensory neurons associated with dysregulation of the voltage-gated sodium channel NaV1.7. In a brain-restricted 6-hydroxydopamine (6-OHDA) model, small-diameter dorsal root ganglion (DRG) neurons exhibited increased sodium current density and altered voltage-dependent inactivation, with the excess current eliminated by selective NaV1.7 blockade. Safinamide directly inhibited a NaV1.7-dependent component of sensory neuron sodium current and reversed established pain-like behaviors. Pharmacological disruption of NaV1.7 regulation by collapsin response mediator protein 2 (CRMP2) normalized DRG hyperexcitability and reversed mechanical and thermal hypersensitivity, whereas genetic disruption of the NaV1.7 CRMP2 regulatory sequence prevented the development of 6-OHDA-induced pain-like behaviors for up to 30 weeks despite preservation of the Parkinsonian motor phenotype. Transcriptomic profiling of human PD DRGs revealed limited global transcriptional remodeling with selective alterations in genes associated with sensory neuron excitability. Together, these findings demonstrate that dopaminergic neurodegeneration initiated within the brain is sufficient to drive persistent peripheral sensory neuron dysfunction and identify CRMP2-dependent regulation of NaV1.7 as a therapeutic target for Parkinsonian pain.
- Open Access
- 18 August 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (9) , 2117-2127
Parabrachial neuropeptide Y Y1 receptor–expressing neurons govern the sensory dimension of neuropathic pain
Pain perception involves complex sensory and emotional processes, yet the supraspinal circuits that sustain neuropathic pain remain incompletely understood. Here, we demonstrate that parabrachial nucleus (PBN) neurons expressing the inhibitory G-protein–coupled neuropeptide Y Y1 receptor ( Npy1r ) are critical modulators of neuropathic pain. Approximately 19% of lateral PBN neurons express Npy1r. Stimulus-evoked Fos activation and calcium dynamics of these neurons increases in mice with spared nerve injury (SNI) compared to sham controls. Pharmacological activation of Y1 receptors or chemogenetic inhibition of Npy1r neurons attenuates SNI-induced mechanical and cold allodynia, without altering baseline sensitivity or conditioned place preference (a measure of affective pain). Preemptive ablation of parabrachial Npy1r neurons before SNI delayed the development of neuropathic hypersensitivity. Conversely, repeated chemogenetic activation of Npy1r neurons produced persistent mechanical and cold hypersensitivity in uninjured animals; this outlasted neuronal activation, indicating sufficiency to drive pain-like states. Viral tracing revealed dense Npy1r projections from lateral parabrachial neurons to forebrain regions including the central amygdala, lateral hypothalamus, zona incerta, and ventromedial thalamus, sites implicated in the sensory and affective dimension of pain. These findings demonstrate that Npy1r -expressing PBN neurons selectively regulate the sensory-discriminative component of neuropathic pain and can maintain long-lasting hypersensitivity even in the absence of injury.
- 18 August 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (9) , 2117-2127
Open AccessParabrachial neuropeptide Y Y1 receptor–expressing neurons govern the sensory dimension of neuropathic pain
Pain perception involves complex sensory and emotional processes, yet the supraspinal circuits that sustain neuropathic pain remain incompletely understood. Here, we demonstrate that parabrachial nucleus (PBN) neurons expressing the inhibitory G-protein–coupled neuropeptide Y Y1 receptor ( Npy1r ) are critical modulators of neuropathic pain. Approximately 19% of lateral PBN neurons express Npy1r. Stimulus-evoked Fos activation and calcium dynamics of these neurons increases in mice with spared nerve injury (SNI) compared to sham controls. Pharmacological activation of Y1 receptors or chemogenetic inhibition of Npy1r neurons attenuates SNI-induced mechanical and cold allodynia, without altering baseline sensitivity or conditioned place preference (a measure of affective pain). Preemptive ablation of parabrachial Npy1r neurons before SNI delayed the development of neuropathic hypersensitivity. Conversely, repeated chemogenetic activation of Npy1r neurons produced persistent mechanical and cold hypersensitivity in uninjured animals; this outlasted neuronal activation, indicating sufficiency to drive pain-like states. Viral tracing revealed dense Npy1r projections from lateral parabrachial neurons to forebrain regions including the central amygdala, lateral hypothalamus, zona incerta, and ventromedial thalamus, sites implicated in the sensory and affective dimension of pain. These findings demonstrate that Npy1r -expressing PBN neurons selectively regulate the sensory-discriminative component of neuropathic pain and can maintain long-lasting hypersensitivity even in the absence of injury.
- Open Access
NRP1 regulates basal nociception: characterization of a peptidergic-specific NRP1 knockout mouse
Neuropilin-1 (NRP1) is a single pass transmembrane glycoprotein that can form a receptor complex with several tyrosine kinase receptors, including the vascular endothelial growth factor (VEGF) receptor. Previous studies have reported that binding of VEGFA to this receptor complex elicits mechanical allodynia and thermal hyperalgesia through potentiation of voltage-gated sodium and calcium channel activity. We find that Nrp1 mRNA and protein is widely distributed in naÏve mouse and rat DRG neurons, including peptidergic afferents. A CGRPcreER: NRP1 fl/fl transgenic mice was generated to investigate the role of peptidergic NRP1 in basal nociception. Following in vivo loss of NRP1, mice are hyposensitive to both noxious heat and mechanical stimuli. Under normal conditions, VEGFA elicits mechanical hypersensitivity, an effect that was absent in our NRP1 knockout mouse. Furthermore, VEGFA induced neuronal hyperexcitability was lost in CGRP expressing neurons isolated from this NRP1 knockout mouse. This study validates the NRP1 knockout mouse and confirms previous findings that VEGFA, often released during pathological pain conditions, requires peptidergic NRP1. Interestingly, we find that in the absence of ongoing injury or inflammation, peptidergic NRP1 regulates basal nociception and pain-like behaviors. Perspective: NRP1 is expressed in sensory neurons including the peptidergic subpopulation. Genetic deletion of NRP1 in healthy adults alters nociception without altering innervation; NRP1 knockout mice are hyposensitive to noxious heat and mechanical stimuli, but lose sensitivity to VEGFA, confirming it is a therapeutic target for growth factor mediated pain conditions.
Open AccessNRP1 regulates basal nociception: characterization of a peptidergic-specific NRP1 knockout mouse
Neuropilin-1 (NRP1) is a single pass transmembrane glycoprotein that can form a receptor complex with several tyrosine kinase receptors, including the vascular endothelial growth factor (VEGF) receptor. Previous studies have reported that binding of VEGFA to this receptor complex elicits mechanical allodynia and thermal hyperalgesia through potentiation of voltage-gated sodium and calcium channel activity. We find that Nrp1 mRNA and protein is widely distributed in naÏve mouse and rat DRG neurons, including peptidergic afferents. A CGRPcreER: NRP1 fl/fl transgenic mice was generated to investigate the role of peptidergic NRP1 in basal nociception. Following in vivo loss of NRP1, mice are hyposensitive to both noxious heat and mechanical stimuli. Under normal conditions, VEGFA elicits mechanical hypersensitivity, an effect that was absent in our NRP1 knockout mouse. Furthermore, VEGFA induced neuronal hyperexcitability was lost in CGRP expressing neurons isolated from this NRP1 knockout mouse. This study validates the NRP1 knockout mouse and confirms previous findings that VEGFA, often released during pathological pain conditions, requires peptidergic NRP1. Interestingly, we find that in the absence of ongoing injury or inflammation, peptidergic NRP1 regulates basal nociception and pain-like behaviors. Perspective: NRP1 is expressed in sensory neurons including the peptidergic subpopulation. Genetic deletion of NRP1 in healthy adults alters nociception without altering innervation; NRP1 knockout mice are hyposensitive to noxious heat and mechanical stimuli, but lose sensitivity to VEGFA, confirming it is a therapeutic target for growth factor mediated pain conditions.
- 18 April 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (6) , 1804-1806
Opposing μ-opioid receptor signalling in spinal NPY microcircuits constrains morphine analgesia
This scientific commentary refers to ‘Distinct contribution of spinal neuropeptide Y and NPY1R neurons to morphine analgesia’ by Wu et al. (https://doi.org/10.1093/brain/awag077).
- 18 April 2026
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (6) , 1804-1806
Opposing μ-opioid receptor signalling in spinal NPY microcircuits constrains morphine analgesia
This scientific commentary refers to ‘Distinct contribution of spinal neuropeptide Y and NPY1R neurons to morphine analgesia’ by Wu et al. (https://doi.org/10.1093/brain/awag077).
- 21 January 2026
- Published by Elsevier in The Journal of Pain
- Vol. 41, 106199
Amygdalar calcitonin gene-related peptide driven effects of cold sensitivity induced by peripheral neuropathy in mice
- 21 January 2026
- Published by Elsevier in The Journal of Pain
- Vol. 41, 106199
Amygdalar calcitonin gene-related peptide driven effects of cold sensitivity induced by peripheral neuropathy in mice
- Top Cited PapersOpen Access
- 8 October 2025
- Published by Springer Nature in Nature
- Vol. 647 (8090) , 689-697
A parabrachial hub for need-state control of enduring pain
Long-term sustained pain following acute physical injury is a prominent feature of chronic pain conditions1. Populations of neurons that rapidly respond to noxious stimuli or tissue damage have been identified in the spinal cord and several nuclei in the brain2,3,4. Understanding the central mechanisms that signal ongoing sustained pain, including after tissue healing, remains a challenge5. Here we use spatial transcriptomics, neural manipulations, activity recordings and computational modelling to demonstrate that activity in an ensemble of anatomically and molecularly diverse parabrachial neurons that express the neuropeptide Y (NPY) receptor Y1 (Y1R neurons) is increased following injury and predicts functional coping behaviour. Hunger, thirst or predator cues suppressed sustained pain, regardless of the injury type, by inhibiting parabrachial Y1R neurons via the release of NPY. Together, our results demonstrate an endogenous analgesic hub at pain-responsive parabrachial Y1R neurons.
- 8 October 2025
- Published by Springer Nature in Nature
- Vol. 647 (8090) , 689-697
Top Cited PapersOpen AccessA parabrachial hub for need-state control of enduring pain
Long-term sustained pain following acute physical injury is a prominent feature of chronic pain conditions1. Populations of neurons that rapidly respond to noxious stimuli or tissue damage have been identified in the spinal cord and several nuclei in the brain2,3,4. Understanding the central mechanisms that signal ongoing sustained pain, including after tissue healing, remains a challenge5. Here we use spatial transcriptomics, neural manipulations, activity recordings and computational modelling to demonstrate that activity in an ensemble of anatomically and molecularly diverse parabrachial neurons that express the neuropeptide Y (NPY) receptor Y1 (Y1R neurons) is increased following injury and predicts functional coping behaviour. Hunger, thirst or predator cues suppressed sustained pain, regardless of the injury type, by inhibiting parabrachial Y1R neurons via the release of NPY. Together, our results demonstrate an endogenous analgesic hub at pain-responsive parabrachial Y1R neurons.
- Open Access
- 29 May 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12, 1603375
Case Report: Adverse reaction to butorphanol in a Collie homozygous for the ABCB1-1∆ (MDR1) mutation
Certain dog breeds, particularly herding breeds like Collies, are predisposed to drug sensitivity due to the ABCB1-1∆ (previously known as MDR1) mutation, which disrupts P-glycoprotein (P-gp) function. This mutation impairs drug efflux at the blood–brain barrier, leading to increased susceptibility to neurotoxic effects. While adverse reactions to P-gp substrate drugs such as macrocyclic lactones and chemotherapeutics are well documented, opioid sensitivity remains poorly understood. This case report documents a Collie that developed severe neurotoxicity, including profound sedation, ataxia, hypersalivation, and seizures, following a single 0.2 mg/kg dose of butorphanol. Symptoms persisted despite supportive care, requiring continuous naloxone administration for approximately 40 h before significant improvement. Neurotoxicological effects may have been exacerbated by metoclopramide and maropitant, known P-gp substrates. This case underscores the need for further research into opioid pharmacokinetics in ABCB1-1∆ mutant dogs and highlights the importance of genetic screening in veterinary practice. To enhance patient safety, integration of automated alerts within electronic medical record systems is recommended to flag high-risk drugs for at-risk breeds, providing real-time warnings, dosing adjustments, and monitoring guidance. These measures could reduce adverse drug reactions and improve clinical outcomes in genetically susceptible dogs.
- 29 May 2025
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 12, 1603375
Open AccessCase Report: Adverse reaction to butorphanol in a Collie homozygous for the ABCB1-1∆ (MDR1) mutation
Certain dog breeds, particularly herding breeds like Collies, are predisposed to drug sensitivity due to the ABCB1-1∆ (previously known as MDR1) mutation, which disrupts P-glycoprotein (P-gp) function. This mutation impairs drug efflux at the blood–brain barrier, leading to increased susceptibility to neurotoxic effects. While adverse reactions to P-gp substrate drugs such as macrocyclic lactones and chemotherapeutics are well documented, opioid sensitivity remains poorly understood. This case report documents a Collie that developed severe neurotoxicity, including profound sedation, ataxia, hypersalivation, and seizures, following a single 0.2 mg/kg dose of butorphanol. Symptoms persisted despite supportive care, requiring continuous naloxone administration for approximately 40 h before significant improvement. Neurotoxicological effects may have been exacerbated by metoclopramide and maropitant, known P-gp substrates. This case underscores the need for further research into opioid pharmacokinetics in ABCB1-1∆ mutant dogs and highlights the importance of genetic screening in veterinary practice. To enhance patient safety, integration of automated alerts within electronic medical record systems is recommended to flag high-risk drugs for at-risk breeds, providing real-time warnings, dosing adjustments, and monitoring guidance. These measures could reduce adverse drug reactions and improve clinical outcomes in genetically susceptible dogs.
- Open Access
Amygdalar Calcitonin Gene-Related Peptide Driven Effects of Cold Sensitivity Induced by Peripheral Neuropathy in Mice
The central nucleus of the amygdala (CeA) is a critical regulator of nociception, and its role in pain modulation depends on factors such as hemispheric location, neuropeptide release, and experimental model. Calcitonin gene-related peptide (CGRP) is a potent neuropeptide modulator within the CeA. Previous research has demonstrated its CeA nociceptive role in migraine, visceral, arthritic, and inflammatory pain murine models. The contribution of CeA CGRP to neuropathic pain is unclear. This study examined the effects of CGRP and its receptor antagonist, CGRP 8-37, in the CeA on mechanical and cold sensitivity in two mouse models of neuropathic pain: chemotherapy-induced peripheral neuropathy (CIPN) mediated by paclitaxel (PTX) and injury-induced neuropathy through the spared nerve injury (SNI) model. Mechanical and cold sensitivity were measured using the hindpaw von Frey and topical acetone drop assays, respectively. Neither CGRP nor CGRP 8-37 in the CeA had any significant effect on mechanical sensitivity in either neuropathic pain model. In the SNI-treated mice, CGRP infusion into either the left or right CeA reduced cold sensitivity in the left and right SNI-treated hindpaw, while CGRP 8-37 infusion into the left or right CeA increased cold sensitivity in the right SNI-treated hindpaw only. In PTX-treated mice, CGRP infusion into the left or right CeA decreased cold sensitivity of the contralateral paw only. These results suggest that CGRP in the CeA influences pain modulation in a complex manner that depends not only on the hemisphere and injury site, but also on the underlying cause of the neuropathic condition. PERSPECTIVE This article presents the anti-nociceptive properties of calcitonin gene-related peptide (CGRP) signaling within the central nucleus of the amygdala during neuropathic pain-like conditions in mice. This dataset can serve to guide novel drug development for treating chronic neuropathic pain conditions. Lateralization of the central nucleus of the amygdala (CeA) is pain-model dependent CGRP signaling within the CeA is correlated with decreased cold sensitivity Different neuropathic etiologies yield differences in CGRP responsiveness
Open AccessAmygdalar Calcitonin Gene-Related Peptide Driven Effects of Cold Sensitivity Induced by Peripheral Neuropathy in Mice
The central nucleus of the amygdala (CeA) is a critical regulator of nociception, and its role in pain modulation depends on factors such as hemispheric location, neuropeptide release, and experimental model. Calcitonin gene-related peptide (CGRP) is a potent neuropeptide modulator within the CeA. Previous research has demonstrated its CeA nociceptive role in migraine, visceral, arthritic, and inflammatory pain murine models. The contribution of CeA CGRP to neuropathic pain is unclear. This study examined the effects of CGRP and its receptor antagonist, CGRP 8-37, in the CeA on mechanical and cold sensitivity in two mouse models of neuropathic pain: chemotherapy-induced peripheral neuropathy (CIPN) mediated by paclitaxel (PTX) and injury-induced neuropathy through the spared nerve injury (SNI) model. Mechanical and cold sensitivity were measured using the hindpaw von Frey and topical acetone drop assays, respectively. Neither CGRP nor CGRP 8-37 in the CeA had any significant effect on mechanical sensitivity in either neuropathic pain model. In the SNI-treated mice, CGRP infusion into either the left or right CeA reduced cold sensitivity in the left and right SNI-treated hindpaw, while CGRP 8-37 infusion into the left or right CeA increased cold sensitivity in the right SNI-treated hindpaw only. In PTX-treated mice, CGRP infusion into the left or right CeA decreased cold sensitivity of the contralateral paw only. These results suggest that CGRP in the CeA influences pain modulation in a complex manner that depends not only on the hemisphere and injury site, but also on the underlying cause of the neuropathic condition. PERSPECTIVE This article presents the anti-nociceptive properties of calcitonin gene-related peptide (CGRP) signaling within the central nucleus of the amygdala during neuropathic pain-like conditions in mice. This dataset can serve to guide novel drug development for treating chronic neuropathic pain conditions. Lateralization of the central nucleus of the amygdala (CeA) is pain-model dependent CGRP signaling within the CeA is correlated with decreased cold sensitivity Different neuropathic etiologies yield differences in CGRP responsiveness
- Open Access
Parabrachial bombesin receptor subtype 3 neurons facilitate heat pain in persistent inflammation
The parabrachial nucleus (PBN) is a critical hub for pain processing that acts as a switchboard for nociceptive signals, relaying them to forebrain regions that integrate sensory signals with affective aspects of pain. Despite strong evidence for the PBN in pain modulation, the heterogeneity of parabrachial neurons poses a challenge in defining their specific contributions. Here, we identify bombesin receptor subtype 3 ( Brs3 )-expressing neurons as a distinct glutamatergic PBN subpopulation involved in inflammatory heat pain. Using Fos expression analysis and in vivo calcium imaging, we demonstrate that Brs3 neurons exhibit heightened activity in response to noxious and innocuous stimuli following an inflammatory insult. Chemogenetic activation of Brs3 neurons in uninjured mice induces pain-like behaviors, indicating their sufficiency in driving nociceptive responses. While inhibition of Brs3 neurons does not reverse inflammatory pain-induced mechanical allodynia, it effectively reduces heat hypersensitivity, suggesting a specific role in thermal pain processing. Brs3 -expressing neurons encompass multiple previously identified pain-related PBN subpopulations, including those expressing the mu opioid receptor ( Oprm1 ), tachykinin 1 receptor ( Tacr1 ), and neuropeptide Y Y1 receptor ( Npy1r ), positioning Brs3 as a potential unifying marker of heat hypersensitivity circuits. These findings provide new insight into the organization of pain-processing networks in the PBN and highlight Brs3 neurons as a crucial population for inflammatory heat pain.
Open AccessParabrachial bombesin receptor subtype 3 neurons facilitate heat pain in persistent inflammation
The parabrachial nucleus (PBN) is a critical hub for pain processing that acts as a switchboard for nociceptive signals, relaying them to forebrain regions that integrate sensory signals with affective aspects of pain. Despite strong evidence for the PBN in pain modulation, the heterogeneity of parabrachial neurons poses a challenge in defining their specific contributions. Here, we identify bombesin receptor subtype 3 ( Brs3 )-expressing neurons as a distinct glutamatergic PBN subpopulation involved in inflammatory heat pain. Using Fos expression analysis and in vivo calcium imaging, we demonstrate that Brs3 neurons exhibit heightened activity in response to noxious and innocuous stimuli following an inflammatory insult. Chemogenetic activation of Brs3 neurons in uninjured mice induces pain-like behaviors, indicating their sufficiency in driving nociceptive responses. While inhibition of Brs3 neurons does not reverse inflammatory pain-induced mechanical allodynia, it effectively reduces heat hypersensitivity, suggesting a specific role in thermal pain processing. Brs3 -expressing neurons encompass multiple previously identified pain-related PBN subpopulations, including those expressing the mu opioid receptor ( Oprm1 ), tachykinin 1 receptor ( Tacr1 ), and neuropeptide Y Y1 receptor ( Npy1r ), positioning Brs3 as a potential unifying marker of heat hypersensitivity circuits. These findings provide new insight into the organization of pain-processing networks in the PBN and highlight Brs3 neurons as a crucial population for inflammatory heat pain.